Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Next Previous
X
Search
Trial Profile

A Two-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tozadenant (Primary)
  • Indications Liver disorders; Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors Biotie Therapies Corp.

    • Most Recent Events

    • 20 Nov 2017 Status changed from recruiting to discontinued, according to an Acorda Therapeutics media release. The company is discontinuing dosing of all participants based on previously disclosed agranulocytosis and associated serious adverse events. the Company concluded that it could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.
    • 14 Jul 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top